EDWARD W. CIOLKO, a partner of the firm, received his law degree from Georgetown University Law Center, and an MBA from the Yale School of Management. He is licensed to practice law in the State of New Jersey, and has been admitted to practice before the United States District Court for the District of New Jersey and the United States Courts of Appeals for the First, Fourth, Ninth and Eleventh Circuits. Mr. Ciolko concentrates his practice in the areas of ERISA, Antitrust, RESPA and Consumer Protection.

Mr. Ciolko is counsel in several pending nationwide ERISA breach of fiduciary duty class actions, brought on behalf of retirement plans and their participants alleging, inter alia, imprudent investment of plan assets which caused significant losses to the retirement savings of tens of thousands of workers. These cases include:  In re Beazer Homes USA, Inc. ERISA Litig., 07-CV-00952-RWS (N.D. Ga. 2007); Nowak v. Ford Motor Co., 240 F.R.D. 355 (E.D. Mich. 2006); Gee v. UnumProvident Corp., 03-1552(E.D. Tenn. 2003); Pettit v. JDS Uniphase Corp. et al., C.A. No. 03-4743 (N.D. Ca. 2003); Hargrave v. TXU, et al., C.A. No. 02-2573 (N.D. Tex. 2002); Evans v. Akers, C.A. No. 04-11380 (D. Mass. 2004); Lewis v. El Paso Corp. No. 02-CV-4860 (S.D. Tex. 2002); and In re Schering-Plough Corp. ERISA Litig. No. 03-CV-1204 (D.N.J. 2003).

Mr. Ciolko’s efforts have also helped achieve a number of large recoveries for affected retirement plan participants: In re Sears Roebuck & Co. ERISA Litig., C.A. No. 02-8324 (N.D. Ill. 2002) (settled — $14.5 million recovery); and In re Honeywell Intern’l ERISA Litig., No. 03-CV-1214 (DRD) (D.N.J. 2003) (settled — $14 million recovery, as well as significant structural relief regarding the plan’s administration and investment of its assets).

Mr. Ciolko has also concentrated part of his practice to the investigation and prosecution of pharma-ceutical antitrust actions, medical device litigation, and related anticompetitive and unfair business practices including In re Wellbutrin SR Antitrust Litigation, 04-CV-5898 (E.D. Pa. Dec. 17, 2004); In re Remeron End-Payor Antitrust Litigation, Master File No. 02-CV-2007 (D.N.J. Apr. 25, 2002); In re Modafinil Antitrust Litigation, 06-2020 (E.D. Pa. May 12, 2006); In re Medtronic, Inc. Implantable Defibrillator Litigation, 05-CV-2700 (D. Minn. 2005); and In re Guidant Corp. Implantable Defibrillator Litigation, 05-CV-2883 (D. Minn. 2005).

Before coming to Barroway Topaz, Mr. Ciolko worked for two and one-half years as a Law Clerk and Attorney Advisor to Commissioner Sheila F. Anthony of the Federal Trade Commission (“FTC”). While at the FTC, Mr. Ciolko reviewed commission actions/investigations and counseled the Commissioner on a wide range of antitrust and consumer protection topics including, in pertinent part: the confluence of antitrust and intellectual property law; research and production of “Generic Drug Entry Prior to Patent Expiration: An FTC Study,” and an administrative complaint against, among others, Schering-Plough Corporation regarding allegedly unlawful settlements of patent litigation which delayed entry of a generic alternative to a profitable potassium supplement (K-Dur).

Edward Ciolko
Main: (610) 667.7706
Direct: (610) 822.0242
Fax: (610) 667.7056
eciolko@btkmc.com
VCard